AstraZeneca PLC (AZN)vsKoninklijke Philips NV ADR (PHG)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
PHG
Koninklijke Philips NV ADR
$24.59
-0.04%
HEALTHCARE · Cap: $25.31B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 247% more annual revenue ($61.37B vs $17.66B). AZN leads profitability with a 17.0% profit margin vs 6.3%. PHG appears more attractively valued with a PEG of 0.79. PHG earns a higher WallStSmart Score of 63/100 (C+).
AZN
Buy60
out of 100
Grade: C+
PHG
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
-55.6%
Fair Value
$20.61
Current Price
$24.59
$3.98 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Earnings expanding 61.4% YoY
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.5% revenue growth
Distress zone — elevated risk
6.3% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : PHG
The strongest argument for PHG centers on EPS Growth, PEG Ratio, Price/Book. PEG of 0.79 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : PHG
The primary concerns for PHG are Revenue Growth, Altman Z-Score, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while PHG is a value play — different risk/reward profiles.
PHG carries more volatility with a beta of 0.91 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
PHG scores higher overall (63/100 vs 60/100). AZN offers better value entry with a 18.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Koninklijke Philips NV ADR
HEALTHCARE · MEDICAL DEVICES · USA
Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?